Dr. Dirk Huebner is Chief Medical Officer and brings three decades of academic and industry-based clinical drug development experience across the biotech and pharmaceutical sectors. He leads Aptevo’s clinical strategy and execution from early-stage studies through late-stage development.

Previously, Dirk served as Chief Medical Officer and Senior Medical Advisor at Mersana (2018–2021), where he built the clinical development department and oversaw the ADC pipeline. Earlier, as Vice President and Head of Development at Boston Biomedical, he assembled a robust clinical team and led multiple early-stage programs, including the napabucasin Phase 3 program. At Millennium/Takeda Oncology, he was Executive Medical Director and global clinical lead for ADCETRIS® (brentuximab vedotin), guiding its European regulatory approval and subsequent registration-enabling studies. He also served as clinical lead for clofarabine in acute myeloid leukemia at Genzyme and held roles of increasing responsibility at Roche and Bristol-Myers Squibb. Dirk holds an M.D. from Freie Universität Berlin and completed his medical residency at the Department of Urology, University Hospital Eppendorf (Hamburg).